PTC Therapeutics, Inc. (PTCT)
| Market Cap | 5.30B -11.9% |
| Revenue (ttm) | 1.16B -35.1% |
| Net Income | -105.97M |
| EPS | -1.28 |
| Shares Out | 83.54M |
| PE Ratio | n/a |
| Forward PE | 29.48 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 502,869 |
| Open | 63.12 |
| Previous Close | 63.36 |
| Day's Range | 62.51 - 63.74 |
| 52-Week Range | 58.80 - 90.87 |
| Beta | 0.51 |
| Analysts | Buy |
| Price Target | 100.47 (+58.25%) |
| Earnings Date | Oct 29, 2026 |
About PTCT
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for PTCT stock is "Buy." The 12-month stock price target is $100.47, which is an increase of 58.25% from the latest price.
News
PTC Therapeutics announces $500M share repurchase program
PTC Therapeutics (PTCT) announced that its Board of Directors has authorized a share repurchase program under which PTC may repurchase up to $500M of the company’s outstanding shares of common…
PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program
WARREN, N.J., Nov. 3, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that its Board of Directors has authorized a share repurchase program under which PTC may repurchase u...
PTC Therapeutics to Participate in Upcoming Investor Conferences
WARREN, N.J., Nov. 2, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Jefferies Global Healthcare Conference Mo...
PTC Therapeutics price target raised to $92 from $91 at JPMorgan
JPMorgan raised the firm’s price target on PTC Therapeutics (PTCT) to $92 from $91 and keeps an Overweight rating on the shares following the Q3 report. Management is confident in…
PTC Therapeutics price target raised to $109 from $108 at Citi
Citi raised the firm’s price target on PTC Therapeutics (PTCT) to $109 from $108 and keeps a Buy rating on the shares.
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J., Oct. 30, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Oct. 28, 2026, the company approved non-statutory stock options to purchase an aggregate of 9....
PTC Therapeutics price target raised to $95 from $90 at TD Cowen
TD Cowen raised the firm’s price target on PTC Therapeutics (PTCT) to $95 from $90 and keeps a Buy rating on the shares. The firm said continued Sephiance growth continues…
PTC Therapeutics Earnings Call Transcript: Q3 2026
Q3 product revenue reached a record $276 million, led by Sephience, and FY 2026 guidance rose. ST-920 adds a near-term Fabry opportunity, while cash flow breakeven remains targeted for 2026.
PTC Therapeutics Earnings release: Q3 2026
PTC Therapeutics released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
PTC Therapeutics Quarterly report: Q3 2026
PTC Therapeutics has published its Q3 2026 quarterly earnings report on October 29, 2026.
PTC Therapeutics reports Q3 EPS (62c), consensus 30c
Reports Q3 revenue $358M, consensus $305.01M. “We delivered another strong quarter of record product revenue led by the continued momentum of the Sephience launch, putting us firmly on track to…
PTC Therapeutics raises 2026 revenue view to $1.29B-$1.32B, consensus $1.26B
16:06 EDT PTC Therapeutics (PTCT) raises 2026 revenue view to $1.29B-$1.32B, consensus $1.26B
PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
– Strong Q3 2026 performance with total revenue of $358 million, including $276 million of product revenue – – Full-year 2026 expected total revenue increased to $1.29 to $1.32 billion, with full-year...
PTC Therapeutics Slides: Corporate presentation
PTC Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 29, 2026.
PTC Therapeutics price target lowered to $106 from $108 at Raymond James
Raymond James lowered the firm’s price target on PTC Therapeutics (PTCT) to $106 from $108 and keeps an Outperform rating on the shares. Sephience remains a key near-term growth driver,…
PTC Therapeutics reinstated with a Hold at Truist
Truist analyst Joon Lee reinstated coverage of PTC Therapeutics (PTCT) with a Hold rating and $62 price target The firm states that it is skeptical about the long-term growth outlook…
PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026
WARREN, N.J., Oct. 15, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its third quarter 2026 financial result...
PTC Therapeutics assumed with a Buy at UBS
UBS analyst Joon Lee assumed coverage of PTC Therapeutics (PTCT) with a Buy rating with a price target of $90, up from $80. The firm states that its Buy thesis…
PTC Therapeutics price target lowered to $75 from $85 at RBC Capital
RBC Capital lowered the firm’s price target on PTC Therapeutics (PTCT) to $75 from $85 and keeps a Sector Perform rating on the shares as part of a broader research…
PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
– Completion of BLA submission expected in Q4 2026 – WARREN, N.J., Sept. 21, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced agre...
PTC Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Sephience’s launch is outperforming prior PKU therapies, driving raised revenue guidance and strong global expansion. Real-world data confirm broad patient benefit, while pipeline programs advance in Friedreich ataxia, Huntington’s, and Fabry disease. Cash position supports continued growth and business development.
PTC Therapeutics upgraded to Outperform from Market Perform at Leerink
Leerink upgraded PTC Therapeutics (PTCT) to Outperform from Market Perform with a price target of $98, up from $70, after assuming coverage of the name. The firm believes Sephience in…
PTC Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
SEPHIENCE's global launch is driving strong commercial growth, with broad patient uptake, high adherence, and sustained expansion into new markets. The pipeline is advancing with promising data in Huntington's disease and innovative RNA splicing programs, while a robust balance sheet supports strategic acquisitions and future profitability.
PTC Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference
Management highlighted strong financials, broad PKU launch success, and a robust rare disease pipeline. International growth is expected to accelerate from 2026, with strategic pricing and reimbursement efforts underway. Recent acquisitions and disciplined OpEx support sustainable profitability.
PTC Therapeutics announces new sephience data
PTC Therapeutics (PTCT) announced that multiple sephience scientific data presentations will be featured at the 2026 Society for the Study of Inborn Errors of Metabolism Annual Symposium, taking place...